NewEdge Advisors’s BioXcel Therapeutics BTAI Stock Holding History

NewEdge Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.78K	Hold	1,331	–	–	﹤0.01%	3826
2025 Q4	$2.13K	Hold	1,331	–	–	﹤0.01%	3876
2025 Q3	$3.41K	Buy	1,331 +1,300	+4,194%	+$4.1K	﹤0.01%	3643
2025 Q2	$57	Hold	31	–	–	﹤0.01%	3925
2025 Q1	$63	Hold	31	–	–	﹤0.01%	3844
2024 Q4	$187	Hold	31	–	–	﹤0.01%	3746
2024 Q3	$305	Hold	31	–	–	﹤0.01%	3654
2024 Q2	$640	Hold	31	–	–	﹤0.01%	3538
2024 Q1	$1.41K	Hold	31	–	–	﹤0.01%	3439
2023 Q4	$1.48K	Hold	31	–	–	﹤0.01%	3402
2023 Q3	$1.26K	Sell	31 -94	-75%	-$9.5K	﹤0.01%	3137
2023 Q2	$13.3K	Buy	125 +62	+98%	+$20.6K	﹤0.01%	2514
2023 Q1	$18.7K	Buy	63 +13	+26%	+$5.55K	﹤0.01%	2363
2022 Q4	$17	Buy	+50	New	+$12.1K	﹤0.01%	3622

Other funds holding BTAI

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

NewEdge Advisors's BTAI Position: Q1 2026 in Review

NewEdge Advisors held its BioXcel Therapeutics (BTAI) position steady in Q1 2026 at 1,331 shares worth $1.78K. The position accounts for ﹤0.01% of the portfolio, ranked #3826.

NewEdge Advisors first reported a position in BTAI in Q4 2022 and has held it in 14 quarters since. The position peaked at $18.7K in Q1 2023. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

NewEdge Advisors held 1,331 shares of BioXcel Therapeutics worth $1.78K as of Q1 2026.
NewEdge Advisors left its BioXcel Therapeutics share count unchanged in Q1 2026.
BioXcel Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3826 holding.
NewEdge Advisors first reported a position in BioXcel Therapeutics in Q4 2022 and has held it in 14 quarters since.
NewEdge Advisors's BioXcel Therapeutics position peaked at $18.7K in Q1 2023.
40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.